An Overview of Bortezomib-Induced Neurotoxicity

Area of Science:

• Oncology
• Pharmacology
• Neuroscience

Background:

• Bortezomib is a proteasome inhibitor used for multiple myeloma.
• It induces tumor cell death by degrading key proteins.
• Bortezomib is the first proteasome inhibitor in clinical practice.

Purpose of the Study:

• To review the pathophysiological mechanisms of bortezomib-induced neuropathy.
• To analyze clinical and pharmacogenetic aspects of bortezomib neuropathy.
• To optimize treatment regimens for multiple myeloma patients.

Main Methods:

• Review of current literature on bortezomib-induced neuropathy.
• Analysis of clinical data and pharmacogenetic studies.
• Discussion of animal models and human studies.

Main Results:

• Bortezomib-induced neuropathy is a dose-limiting toxicity.
• Subcutaneous administration or dose modification can reduce neuropathy.
• Understanding mechanisms is crucial for optimizing treatment.

Conclusions:

• Further research into bortezomib neuropathy mechanisms is needed.
• Clinical and pharmacogenetic analysis can guide treatment optimization.
• Optimized regimens will improve patient outcomes in multiple myeloma.